Patents
Literature
8 results about "Predictive marker" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A predictive marker is a particular protein or gene that indicates sensitivity or resistance to a specific therapy. The use of predictive markers is becoming increasingly relevant in cancer therapy as it allows for better identification of patients who will respond positively to the therapy. In the clinical setting, predictive markers are limited to use in breast cancer. Expression of estrogen and progesterone receptors can determine the benefits of hormone therapy, whilst the benefit of treating breast cancer patients with herceptin (Trastuzumab) is determined by the expression of HER2. There are many advantages to utilizing a predictive marker in cancer therapy including better patient management minimizing unnecessary suffering from side effects with ultimately the wrong treatment choice, reducing loss of precious time whilst determining whether a therapy will provide any benefit, and a reduction in cost to both the patient and the wider health community.
Application of intestinal flora metabolite salicylic acid in prediction marker of Escherichia coli calf diarrhea
The invention discloses an application of intestinal flora metabolite salicylic acid as a predictive marker of Escherichia coli calf diarrhea. The obviously up-regulated metabolite salicylic acid is screened out from the diarrhea calf feces through a non-targeted metabonomics technology, and in a group of new independent samples, it is verified through an ELISA test that the salicylic acid concentration of the diarrhea calf feces is obviously higher than that of a healthy group. ROC curve analysis shows that the area under curve (AUC) of SA for predicting escherichia coli calf diarrhea is 0.8148, and the method has good prediction capability. The invention provides a non-invasive, cheap, rapid and high-specificity prediction method, can be used for early warning and auxiliary diagnosis of Escherichia coli calf diarrhea, and has important significance for guiding clinical precise medication and reducing the death rate of calves.
Owner:YUNNAN AGRICULTURAL UNIVERSITY
Immunotherapy response predictive marker RBM28 and application thereof in combined therapy sensitization
PendingCN121955380Aachieve healingEnhance the efficacy of immunotherapyOrganic active ingredientsInorganic active ingredientsParanasal Sinus CarcinomaPhosphorylation
The invention belongs to the technical field of biological medicine, and provides an immunotherapy response prediction marker RBM28 and application thereof in combined treatment sensitization, the application is characterized in that the expression level of RBM28 is used as an evaluation index, a TG003 and PD-1 or ATO and PD-1 combined inhibitor is used for in-vitro treatment of esophageal squamous carcinoma tumor cells and mouse models, and the immunotherapy response prediction marker RBM28 can be used for immunotherapy sensitization. The immunotherapy prediction effect of the RBM28 expression level as an evaluation index on the esophageal squamous cell carcinoma and the treatment effect of the TG003 and PD-1 or ATO and PD-1 combined inhibitor on the esophageal squamous cell carcinoma are evaluated; results show that high expression of RBM28 is related to development of various tumors, and RBM28 can be used as an immunotherapy response prediction marker; the inhibitor can be used for jointly treating esophageal squamous cell carcinoma, inhibiting RBM28 phosphorylation, inducing immune activation, enhancing the curative effect of immunotherapy and remarkably reducing the tumor volume so as to achieve the purpose of treating esophageal squamous cell carcinoma.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
Application of sTREM2 as marker in vulnerable plaque diagnosis model and reagent
According to the application of the serological biomarker in preparation of the vulnerable plaque diagnostic kit, the serological biomarker comprises sTREM2. Human peripheral blood serum is collected, and the concentration of soluble myeloid cell triggered receptor 2 (sTREM2) in the serum is determined by using an enzyme-linked immunosorbent assay (ELISA) kit or an equivalent immunoassay method, so that early discovery and (dynamic) monitoring of vulnerable plaques are realized. Through verification, the sTREM2 is suitable for being used as a diagnosis and prediction marker of vulnerable plaque related diseases, and guidance is provided for further clinical diagnosis (such as OCT / IVUS) and treatment.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Application of 5, 6-EET as predictive marker of triple-negative breast cancer lung metastasis
The invention provides an application of 5, 6-EET as a predictive marker of triple negative breast cancer pulmonary metastasis, and 5, 6-EET promotes triple negative breast cancer pulmonary metastasis. And 5, 6-EET promotes lung metastasis of triple-negative breast cancer by enhancing the permeability of pulmonary vessels. The 5, 6-EET promotes TNBC cells to generate pulmonary parenchyma metastasis by enhancing the permeability of mouse pulmonary vessels, and the discovery helps people to understand the scientific significance of arachidonic acid metabolism reprogramming in the TNBC pulmonary metastasis process, clarifies the molecular mechanism of 5, 6-EET metabolism in the TNBC pulmonary metastasis process, and provides a potential reference index for predicting the pulmonary metastasis risk.
Owner:NANKAI UNIV
Oral bacterial markers associated with colorectal cancer prognosis and uses thereof
ActiveCN119955959BMicrobiological testing/measurementMicroorganism based processesOncologyPredictive marker
This invention belongs to the field of biomedical technology and discloses oral bacterial biomarkers related to colorectal cancer and their applications. This invention provides oral bacterial biomarkers associated with the prognosis of colorectal cancer, wherein the bacteria include at least one of *Campylobacter gracilis*, *Neisseria oralis*, and *Treponema medium*. It also provides the application of the above-mentioned oral bacterial biomarkers as prognostic predictive markers for colorectal cancer, and the application of reagents for detecting oral bacteria in the preparation of products predicting the prognosis of colorectal cancer. Through in-depth research, this invention has discovered that some oral bacteria are significantly correlated with the progression of colorectal cancer and can effectively predict the progression and prognosis of colorectal cancer, providing a reference for the prognosis of colorectal cancer and offering a promising target and direction for the future diagnosis and treatment of colorectal cancer.
Owner:SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)
Predictive marker for epithelial cancer
The present invention relates to a method of predicting the clinical outcome of a subject diagnosed with epithelial cancer, such as oral squamous cell carcinoma, and biomarkers for use in the method.
Owner:UNIVERSITY OF TURKU
Use of plasma osteocalcin as a biomarker in the preparation of a product for the diagnosis and / or prognosis of sepsis in children
The present application relates to the use of plasma osteocalcin as a biomarker in the preparation of a diagnostic and / or prognostic product for sepsis in children. The prognostic product uses the measurement of osteocalcin levels on the first day of admission of a child with sepsis to assess the degree of organ dysfunction and the need for organ support in patients with sepsis. The present application discloses the potential of osteocalcin as a modulator of the immune inflammatory response in sepsis and that its level changes can be used as a predictive marker of the diagnosis and clinical outcome of sepsis. This finding provides a new biomarker for the early diagnosis, prognosis evaluation and treatment of sepsis and an important basis for clinical management.
Owner:SHANGHAI INSTITUTE OF INFECTIOUS DISEASE & BIOSECURITY
Use of induced sputum CC16 as a predictive marker for severity of COPD and eosinophilic subtypes
ActiveCN116287215BMicrobiological testing/measurementMedical automated diagnosisEosinophilic GranulocytePredictive marker
The application discloses an application of inducing sputum CC16 as a prediction marker of COPD severity and eosinophil subtype. The application finds that the expression of CC16 in induced sputum of mild and moderate COPD patients and severe and very severe COPD patients has significant difference by detecting and analyzing various inflammatory molecules in induced sputum, and can distinguish eosinophilic COPD. The application establishes a regression model based on FEV1pred% and the relative expression level of CC16 mRNA, and the model has good sensitivity, specificity and accuracy. Therefore, the mRNA level of induced sputum CC16 has good application prospect for evaluating the severity of COPD and diagnosing the eosinophil subtype. The application can evaluate the severity of COPD and diagnose the eosinophil subtype in a more simple way, and based on the characteristics of the biomarker, a more reliable non-invasive kit can be prepared.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV